Home
NewsNewsINVO Fertility acquires Family Beginnings in a strategic move to expand its U.S. footprint and strengthen patient-centered reproductive care. The acquisition integrates advanced IVF and INVOcell services, reinforces operational growth, and ensures leadership continuity under Dr. James Donahue within INVO’s expanding clinical network.
Feb. 19, 2026 – INVO Fertility, a leader in expanding access to assisted reproductive technology, announced the successful closing of its acquisition of Family Beginnings, P.C. This finalization marks the completion of the strategic transaction first detailed in the company's previous announcement.
The acquisition of the Indiana-based clinic was executed according to the terms of the definitive purchase agreement, with INVO acquiring the non-clinical assets for a combined purchase price of $760,000, $1 million in revenue, and $0.2 million in net income for the nine months ending September 30, 2025. This performance accounted for nearly 18% of INVO’s total clinic revenue during that period.
INVO Fertility acquires Family Beginnings with a clear focus on maintaining the high standard of personalized, patient-first care for which the clinic is known. To ensure a seamless transition and continuity of care, James Donahue, M.D., the clinic’s REI and lab director, has entered into a multi-year agreement to continue leading operations. Dr. Donahue, recently recognized as a 2026 Castle Connolly Top Doctor, brings decades of expertise to the INVO network.
The clinic offers a comprehensive suite of reproductive services, including traditional IVF, ovulation induction, and intrauterine insemination. Notably, Family Beginnings was an early adopter of INVO’s proprietary INVOcell solution, an intravaginal culture (IVC) procedure that allows fertilization to take place in vivo within the woman’s body.
Steve Shum, CEO of INVO Fertility, highlighted the strategic importance of the deal, stating that it expands the company’s geographic footprint while advancing its mission to provide affordable, high-quality fertility care. The closing follows a period of "meaningful progress" for the company, as INVO continues to execute a growth strategy centered on both organic initiatives and targeted acquisitions.
By integrating Family Beginnings into its growing network of operational U.S. clinics, INVO Fertility aims to leverage its broader clinical resources and ongoing investment in advanced technologies to support patients through the emotional journey of reproductive treatment.
Luna and Kindbody are redefining Intelligence in Fertility Care through a strategic partnership that integrates wearable biomarker tracking into clinical pathways. By capturing real-time physiological data, the collaboration enables personalised insights, enhances decision-making, and creates a more connected, data-driven fertility journey for patients and care providers alike.
Sapyen and Avenues launch at-home fertility diagnostics, introducing a couple-first testing model in the UK. By integrating semen analysis and AMH testing into early care, this approach reduces clinic visits, accelerates diagnosis, and ensures balanced fertility evaluation, transforming how patients begin their reproductive health journey.
Nexpring Health has invested in May Health to accelerate the development of the Anavi™ System, a novel device designed to treat PCOS-Related Infertility. The technology aims to restore ovulation through a single office-based procedure, expanding treatment options for millions of women affected by polycystic ovary syndrome.
INVO Fertility would be introducing time-lapse incubation technology at its Wisconsin clinic, hence offering high-quality lab care, creative patient solutions, and advanced embryo monitoring for improved fertility results.
Costco, Sesame, and IVI RMA North America have announced strategic partnership to alter fertility care in the U.S. by removing biggest obstacles to care including high costs and limited access.
Carea has launched its Trying to Conceive - IVF/IUI mode to help women undergoing intricate fertility treatment with risks of inconsistent clinic continuity through continuous tracking and expert guidance.
The Minnesota bill for infertility treatments mandates comprehensive insurance coverage for diagnosis, IVF, and fertility preservation across public and private health plans. Set for implementation in 2027, the legislation expands access, modernises infertility definitions, and ensures cost-sharing protections to make reproductive healthcare more equitable.
